Finch Therapeutics Group, Inc. Banner Image

Finch Therapeutics Group, Inc.

  • Ticker FNCH
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Finch Therapeutics Group, Inc. Logo Image
  • 11-50 Employees
  • Based in Somerville, Massachusetts
Finch Therapeutics has a portfolio of microbiome assets including CP101, a late-stage, investigational, orally administered microbiome candidate with positive clinical data from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI). Additionally, Finch has pre-clinical assets that are designed to target ulcerative colitisMore, Crohn’s disease, and autism spectrum disorder. Finch has a robust intellectual property estate reflecting the Company’s pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. In January 2023, Finch announced a decision to discontinue its Phase 3 trial of CP101 in recurrent CDI and focus on realizing the value of its intellectual property estate and other assets.
5.0 / 5.0 (4)

Finch Therapeutics Group, Inc. reports have an aggregate usefulness score of 5.0 based on 4 reviews.

Finch Therapeutics Group, Inc.

Most Recent Annual Report

Finch Therapeutics Group, Inc.
MOST RECENT 2023 Annual Report and Form 10K

Older/Archived Annual Reports

Finch Therapeutics Group, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!